'Warfarin therapy' presentation slideshows

1.35k views • 134 slides

Clinical Scenario

Clinical Scenario.

592 views • 48 slides

Management of Oral Anticoagulant Therapy

Management of Oral Anticoagulant Therapy. Principles & Practice. Prepared for the Postgraduate Education Committee, Council on Clinical Cardiology American Heart Association by. Jack Ansell, M.D. Jack Hirsh, M.D. Nanette K. Wenger, M.D.

527 views • 48 slides

AHA 2003: Exchanging knowledge

AHA 2003: Exchanging knowledge. Valentin Fuster MD Director, Cardiovascular Institute Mount Sinai Medical Center New York, NY Robert Harrington MD Professor of Medicine Duke University Medical Center Durham, NC James Ferguson MD Associate Director, Cardiology

472 views • 47 slides

UMASS Memorial Health Care Improving Patient Care Management

UMASS Memorial Health Care Improving Patient Care Management. Pamela Burgwinkle APRN-BC, CACP Presented November 4, 2008. Historical Perspective. Coordinated Anticoagulation Clinics in United States Since 1950 UMass Medical Center (UMMC) Established 1970s Point of Care (POC) Testing 1980s

693 views • 46 slides

Management of Oral Anticoagulant Therapy

Management of Oral Anticoagulant Therapy. Principles & Practice. Clotting Cascade. Vitamin K-Dependent Clotting Factors. Vitamin K. VII. Synthesis of Functional Coagulation Factors. IX. X. II. Vitamin K Mechanism of Action. Warfarin Mechanism of Action. Vitamin K. Antagonism of

1.09k views • 44 slides

Safer Anticoagulation Therapy

1.49k views • 43 slides

The clinician has two worries when decided to treat PE !

VENOUS THROMBOEMBOLISM TREATMENT Numan EK?M M.D. Gazi University Medical School Chest Diseases Department. The clinician has two worries when decided to treat PE !. Over dosage TREATMENT Low dosage. hemorrhage. recurrence. Pulmonary embolism. not treated !

552 views • 43 slides

MANAGEMENT OF CARDIAC SURGICAL PATIENTS RECEIVING PLATELET INHIBITORS

MANAGEMENT OF CARDIAC SURGICAL PATIENTS RECEIVING PLATELET INHIBITORS. Jerrold H. Levy, MD Professor of Anesthesiology Emory University School of Medicine Director of Cardiothoracic Anesthesiology Emory Healthcare Atlanta, Georgia. Events Leading to Thrombus Formation. Adhesion .

441 views • 38 slides

Hot Topics In Anticoagulation

Hot Topics In Anticoagulation. Deborah Zeitlin, Pharm.D. Assistant Professor of Pharmacy Practice Butler University College of Pharmacy and Health Sciences Clinical Pharmacist Specialist, Clarian Health. Disclosure Statement.

624 views • 38 slides

This is where the title would go.

369 views • 30 slides

Involvement of genetics in poor outcomes in anticoagulation therapy

Involvement of genetics in poor outcomes in anticoagulation therapy. Farhad Kamali Thrombosis & Anticoagulation Research Group Institute of Cellular Medicine. Introduction. Warfarin a widely used oral anticoagulant for treatment and prophylaxis of thromboembolism (e.g. DVT)

304 views • 28 slides

WARFARIN

WARFARIN. AN OVERVIEW. HEMOSTASIS. VASCULAR SPASM PLATELET PLUG BLOOD COAGULATION GROWTH OF FIBROUS TISSUE IN CLOT. WHEN DOES BLOOD COAGULATE?. Procoagulants > Anticoagulants Injury to blood vessel Blood stasis. INITIATION OF BLOOD COAGULATION. Extrinsic Pathway. Intrinsic Pathway.

1.08k views • 27 slides

WARFARIN

WARFARIN. AN OVERVIEW. HEMOSTASIS. VASCULAR SPASM PLATELET PLUG BLOOD COAGULATION GROWTH OF FIBROUS TISSUE IN CLOT. WHEN DOES BLOOD COAGULATE?. Procoagulants > Anticoagulants Injury to blood vessel Blood stasis. INITIATION OF BLOOD COAGULATION. Extrinsic Pathway. Intrinsic Pathway.

494 views • 27 slides

Warfarin therapy in intravenous drug abusers

Warfarin therapy in intravenous drug abusers. Dewsbury and District Hospital Anticoagulant Service. The Problem. INR. Case History(1). 32 y Male Heroin addict for 8 years Extensive Femoral vein thrombosis associated with a groin abscess at an injection site.

675 views • 20 slides

Genetics and Genomics in Clinical Medicine

Genetics and Genomics in Clinical Medicine. Raju Kucherlapati, Ph.D. Harvard Medical School Partners Healthcare. Healthcare Issues. Healthcare costs are rising rapidly Costs of drug development at all time high Estimated cost of a new drug 800 MM Drugs are not effective in all patients

447 views • 17 slides

AF and NOACs An UPDATE JULY 2014

AF and NOACs An UPDATE JULY 2014. Helen Williams Consultant Pharmacist for CV Disease South London. AF and stroke risk. % of strokes attributable to AF. AF is the leading - and most preventable - cause of embolic stroke Risk increases with ? a ge

298 views • 16 slides

Big and Breathless

Big and Breathless. Quizzzzzzzzzzzzz. What is the most common presenting complaint for a patient with a PE? Chest pain Cough Dyspnoea Leg pain Syncope. Which item is not a Wells criterion for DVT? Active cancer Lower limb paralysis Varicose veins Previous DVT

249 views • 13 slides

SMALL INCISION MANUAL ECCE (BLUMENTHAL TECHNIQUE) IN PATIENTS ON WARFARIN THERAPY

SMALL INCISION MANUAL ECCE (BLUMENTHAL TECHNIQUE) IN PATIENTS ON WARFARIN THERAPY. Yossi Yatziv M.D., Moshe Lazar M.D. Tel Aviv Medical Center. Background. The use of Warfarin in the elderly population undergoing cataract surgery is not uncommon

851 views • 12 slides

Reversal of Vitamin-K Antagonists

Reversal of Vitamin-K Antagonists. Guidelines for Management for Nontherapeutic INR for patient on Warfarin Therapy. Case AF ???? 73 ?? INR 7.30 PT 68.20 - > No bleeding Off warfarin 2 ??? Vitamin K 2 mg PO. Vitamin K 1 ( Phytomenadione ). 2 mg / 0.2 ml. 10 mg / 1 ml. Oral route

397 views • 9 slides